

Alan A Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10516448/publications.pdf>

Version: 2024-02-01

220
papers

16,474
citations

10070

75
h-index

20625

120
g-index

227
all docs

227
docs citations

227
times ranked

12106
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1421-1427.	2.8	10
2	Peripheral benzodiazepine receptor/18ÅkDa translocator protein positron emission tomography imaging in a rat model of acute brain injury. <i>Annals of Nuclear Medicine</i> , 2021, 35, 8-16.	1.2	3
3	Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. <i>Addiction Biology</i> , 2020, 25, e12812.	1.4	9
4	Replicating predictive serum correlates of greater translocator protein distribution volume in brain. <i>Neuropsychopharmacology</i> , 2020, 45, 925-931.	2.8	20
5	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	0.7	18
6	Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans. <i>Neuropsychopharmacology</i> , 2019, 44, 1284-1290.	2.8	13
7	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	6.0	74
8	Small Molecules as Radiopharmaceutical Vectors. , 2019, , 119-136.		8
9	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. <i>Schizophrenia Research</i> , 2019, 213, 80-86.	1.1	8
10	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 111-119.	1.4	26
11	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , 2018, 5, 339-347.	3.7	192
12	Interaction between TSPO a neuroimmune marker and redox status in clinical high risk for psychosis: a PET-MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	2.8	22
13	Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 503-512.	1.0	9
14	Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 542-551.	2.3	26
15	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	3.7	32
16	TSPO expression and brain structure in the psychosis spectrum. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 79-85.	2.0	17
17	A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [11C]-(+)-PHNO. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1112-1119.	1.4	7
18	Investigating the effects of norepinephrine β 1 receptor blockade on dopamine levels: A pilot PET study with [¹¹ C]-(+)-PHNO in controls. <i>Synapse</i> , 2017, 71, e21968.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 833.	6.0	132
20	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [¹⁸ F]FEPPA. <i>Neuropsychopharmacology</i> , 2017, 42, 2474-2481.	2.8	47
21	Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 23-29.	2.5	10
22	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	4.0	103
23	Increased Seasonal Variation in Serotonin Transporter Binding in Seasonal Affective Disorder. <i>Neuropsychopharmacology</i> , 2016, 41, 2447-2454.	2.8	40
24	Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users. <i>Neuropsychopharmacology</i> , 2016, 41, 2994-3002.	2.8	62
25	Amyloid deposition in semantic dementia: a positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1064-1074.	1.3	9
26	Estimating the effect of endogenous dopamine on baseline [¹¹ C](+)-PHNO binding in the human brain. <i>Synapse</i> , 2016, 70, 453-460.	0.6	12
27	¹¹ C bonds made easily for positron emission tomography radiopharmaceuticals. <i>Chemical Society Reviews</i> , 2016, 45, 4708-4726.	18.7	98
28	Association of ventral striatum monoamine oxidase-A binding and functional connectivity in antisocial personality disorder with high impulsivity: A positron emission tomography and functional magnetic resonance imaging study. <i>European Neuropsychopharmacology</i> , 2016, 26, 777-786.	0.3	26
29	D ₃ dopamine receptor-preferring [¹¹ C]PHNO PET imaging in Parkinson patients with dyskinesia. <i>Neurology</i> , 2016, 86, 224-230.	1.5	49
30	Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition. <i>Biological Psychiatry</i> , 2016, 79, 117-126.	0.7	35
31	Monoamine Oxidase-A Occupancy by Moclobemide and Phenzelzine: Implications for the Development of Monoamine Oxidase Inhibitors. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv078.	1.0	27
32	Occupancy of Dopamine D3 and D2 Receptors by Bupirone: A [¹¹ C](+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2016, 41, 529-537.	2.8	24
33	Lack of Age-Dependent Decrease in Dopamine D3 Receptor Availability: A [¹¹ C](+)-PHNO and [¹¹ C]-Raclopride Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1812-1818.	2.4	26
34	Human Kinetic Modeling of the 5HT ₆ PET Radioligand ¹¹ C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT ₆ and 5HT _{2A} Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1901-1909.	2.8	24
35	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	1.1	95
36	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [¹⁸ F]-FEPPA. <i>Schizophrenia Bulletin</i> , 2015, 41, 85-93.	2.3	158

#	ARTICLE	IF	CITATIONS
37	[¹¹ C]-(+)-PHNO PET imaging of dopamine D _{2/3} receptors in Parkinson's disease with impulse control disorders. <i>Movement Disorders</i> , 2015, 30, 160-166.	2.2	65
38	Dopamine D _{2/3} receptor availability in the striatum of antipsychotic-free older patients with schizophrenia: A [¹¹ C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	1.1	17
39	Relationship of Monoamine Oxidase-A Distribution Volume to Postpartum Depression and Postpartum Crying. <i>Neuropsychopharmacology</i> , 2015, 40, 429-435.	2.8	67
40	Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [¹¹ C] Harmine Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2015, 40, 2596-2603.	2.8	60
41	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. <i>JAMA Psychiatry</i> , 2015, 72, 268.	6.0	700
42	Radiosynthesis and ex vivo evaluation of [¹⁸ F]-(<i>S</i>)-3-(6-(3-fluoropropoxy)benzo[<i>d</i>]isoxazol-3-yl)-5-(methoxymethyl)oxazolidin-2-one for imaging MAO-B with PET. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 288-291.	1.0	15
43	Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms. <i>Neuropsychopharmacology</i> , 2014, 39, 973-980.	2.8	53
44	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 883-889.	2.4	83
45	Heightened D ₃ Dopamine Receptor Levels in Cocaine Dependence and Contributions to the Addiction Behavioral Phenotype: A Positron Emission Tomography Study with [¹¹ C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 311-318.	2.8	99
46	Recent methods for measuring dopamine D ₃ receptor occupancy in vivo: importance for drug development. <i>Frontiers in Pharmacology</i> , 2014, 5, 161.	1.6	38
47	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸ F]-FEPPA. <i>Synapse</i> , 2014, 68, 536-547.	0.6	17
48	Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11-Labeled Harmine Positron Emission Tomography. <i>JAMA Psychiatry</i> , 2014, 71, 873.	6.0	58
49	Whole-Body Radiation Dosimetry of ¹¹ C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1993-1997.	2.8	15
50	Greater Monoamine Oxidase A Binding in Alcohol Dependence. <i>Biological Psychiatry</i> , 2014, 75, 756-764.	0.7	21
51	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [¹¹ C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	2.8	54
52	Radiosynthesis and ex vivo evaluation of [¹¹ C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 688-694.	0.3	34
53	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	2.8	86
54	¹¹ C ¹⁸ O ₂ fixation: a renaissance in PET radiochemistry. <i>Chemical Communications</i> , 2013, 49, 5621.	2.2	92

#	ARTICLE	IF	CITATIONS
55	Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. <i>Pharmacological Research</i> , 2013, 70, 66-71.	3.1	24
56	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18KDa). <i>Molecular Imaging and Biology</i> , 2013, 15, 353-359.	1.3	23
57	Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 863-871.	2.4	173
58	Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase. <i>Nuclear Medicine and Biology</i> , 2013, 40, 740-746.	0.3	28
59	The D _{2/3} dopamine receptor in pathological gambling: a positron emission tomography study with [¹¹ C]-(+)-propylhexahydro- α -naphtho- α -oxazin and [¹¹ C]-raclopride. <i>Addiction</i> , 2013, 108, 953-963.	1.7	167
60	Positron-Emission Tomography Imaging of the TSPO with [¹⁸ F]FEPPA in a Preclinical Breast Cancer Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 254-259.	0.7	17
61	Radiosynthesis and Evaluation of [¹¹ C]-Carbonyl-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 201-209.	2.9	42
62	Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4351-4357.	1.4	29
63	Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 98-106.	1.4	36
64	Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 407-414.	2.4	65
65	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	2.4	10
66	Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [11C]-(+)-PHNO PET Study. <i>PLoS ONE</i> , 2013, 8, e60382.	1.1	11
67	Translocator Protein (18KDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 968-972.	2.4	131
68	Whole-Body Distribution and Radiation Dosimetry of [¹¹ C]-(+)-PHNO, a D _{2/3} Agonist Ligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1802-1806.	2.8	1
69	Convergent Effects of Acute Stress and Glucocorticoid Exposure upon MAO-A in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 17120-17127.	1.7	29
70	Dynamic, Adaptive Changes in MAO-A Binding after Alterations in Substrate Availability: An <i>in vivo</i> [¹¹ C]-Harmine Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 443-446.	2.4	27
71	Higher Binding of the Dopamine D ₃ Receptor-Preferring Ligand [¹¹ C]-(+)-Propyl-Hexahydro-Naphtho-Oxazin in Methamphetamine Polydrug Users: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2012, 32, 1353-1359.	1.7	152
72	Synthesis and PET imaging studies of [18F]2-fluoroquinolin-8-ol ([18F]CABS13) in transgenic mouse models of Alzheimer's disease. <i>MedChemComm</i> , 2012, 3, 1228.	3.5	29

#	ARTICLE	IF	CITATIONS
73	Development of new carbon-11 labelled radiotracers for imaging GABAA- and GABAB-benzodiazepine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4482-4488.	1.4	25
74	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	0.7	222
75	Biodistribution and Radiation Dosimetry of the Serotonin 5-HT ₆ Ligand [¹¹ C]GSK215083 Determined from Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2012, 14, 517-521.	1.3	7
76	Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [¹¹ C-carbonyl]AR-A014418 by [¹¹ C]CO ₂ fixation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2099-2101.	1.0	33
77	Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. <i>Journal of Psychiatric Research</i> , 2012, 46, 890-897.	1.5	26
78	Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 1016-1025.	0.6	27
79	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [¹¹ C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.	1.1	78
80	[¹¹ C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2011, 38, 247-253.	0.3	76
81	Development of new radiopharmaceuticals for imaging monoamine oxidase B. <i>Nuclear Medicine and Biology</i> , 2011, 38, 933-943.	0.3	40
82	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	2.4	98
83	Distribution of Vesicular Monoamine Transporter 2 Protein in Human Brain: Implications for Brain Imaging Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 2065-2075.	2.4	23
84	Isoflurane Anaesthesia Differentially Affects the Amphetamine Sensitivity of Agonist and Antagonist D ₂ /D ₃ Positron Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine Release. <i>Molecular Imaging and Biology</i> , 2011, 13, 737-746.	1.3	26
85	A rapid one-step radiosynthesis of [¹¹ C]d-threo-methylphenidate. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 168-170.	0.5	3
86	Radiosynthesis of [¹¹ C]SL25.1188 via [¹¹ C]CO ₂ fixation for imaging monoamine oxidase B. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 678-680.	0.5	67
87	Synthesis and Application of Isocyanates Radiolabeled with Carbon-11. <i>Chemistry - A European Journal</i> , 2011, 17, 259-264.	1.7	73
88	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [¹¹ C]-harmine PET study. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 375-382.	1.4	49
89	Monoamine Oxidase A Binding in the Prefrontal and Anterior Cingulate Cortices During Acute Withdrawal From Heavy Cigarette Smoking. <i>Archives of General Psychiatry</i> , 2011, 68, 817.	13.8	67
90	Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[¹¹ C]DTBZ study in humans. <i>Synapse</i> , 2010, 64, 417-420.	0.6	19

#	ARTICLE	IF	CITATIONS
91	Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT. <i>Molecules</i> , 2010, 15, 8260-8278.	1.7	53
92	Side Effects Profile in Humans of ¹¹ C-(+)-PHNO, a Dopamine D _{2/3} Agonist Ligand for PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 496-497.	2.8	19
93	Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period. <i>Archives of General Psychiatry</i> , 2010, 67, 468.	13.8	177
94	Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals "Radiosynthesis and ex vivo biodistribution of [¹⁸ F]3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine. <i>Canadian Journal of Chemistry</i> , 2010, 88, 1222-1232.	0.6	5
95	Evaluation of ¹¹ C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1021-1029.	2.8	68
96	The Antipsychotics Olanzapine, Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro. <i>Neuropsychopharmacology</i> , 2010, 35, 1826-1835.	2.8	57
97	Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[¹¹ C]DASB and structural brain imaging study. <i>Brain</i> , 2010, 133, 1779-1797.	3.7	134
98	Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [¹¹ C]PHNO, and a Selective D3 Receptor Antagonist. <i>Biological Psychiatry</i> , 2010, 68, 392-399.	0.7	140
99	Radiosynthesis and ex vivo evaluation of (R)-(α^*)-2-chloro-N-[1- ¹¹ C-propyl]n-propylnorapomorphine. <i>Nuclear Medicine and Biology</i> , 2010, 37, 35-40.	0.3	2
100	Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[¹¹ C]SKF 82957. <i>Nuclear Medicine and Biology</i> , 2010, 37, 837-843.	0.3	15
101	Direct fixation of [¹¹ C]-CO ₂ by amines: formation of [¹¹ C-carbonyl]-methylcarbamates. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 428-432.	1.5	64
102	Brain Monoamine Oxidase A Binding in Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2009, 66, 1304.	13.8	166
103	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	13.8	97
104	Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. <i>Journal of Nuclear Medicine</i> , 2009, 50, 900-908.	2.8	84
105	Decreased binding of the D3 dopamine receptor-preferring ligand [¹¹ C]-(+)-PHNO in drug-naive Parkinson's disease. <i>Brain</i> , 2009, 132, 1366-1375.	3.7	93
106	D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [¹¹ C]-Raclopride PET Study in Cats. <i>Neuropsychopharmacology</i> , 2009, 34, 662-671.	2.8	78
107	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [¹¹ C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	2.8	109
108	Utility of commercial radiosynthetic modules in captive solvent [¹¹ C] α -methylation reactions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2009, 52, 490-492.	0.5	31

#	ARTICLE	IF	CITATIONS
109	In vivo quantification of regional dopamine D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. <i>Synapse</i> , 2009, 63, 782-793.	0.6	127
110	Ex vivo [¹¹ C](+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. <i>Synapse</i> , 2009, 63, 998-1009.	0.6	23
111	An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. <i>Applied Radiation and Isotopes</i> , 2009, 67, 611-616.	0.7	20
112	Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scylo-inositol. <i>Chemical Communications</i> , 2009, , 5527.	2.2	17
113	Dopamine modulating drugs influence striatal (+)-[¹¹ C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. <i>Synapse</i> , 2008, 62, 873-876.	0.6	42
114	Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [¹¹ C]DASB. <i>Movement Disorders</i> , 2008, 23, 1776-1780.	2.2	155
115	Brain region binding of the D2/3 agonist [11C](+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	1.9	95
116	Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5277-5284.	1.4	15
117	Synthesis and preliminary evaluation of [18F]-fluoro-(2S)-Exaprolol for imaging cerebral Î2-adrenergic receptors with PET. <i>Neurochemistry International</i> , 2008, 53, 173-179.	1.9	10
118	Dopamine D2 receptor radiotracers [11C](+)-PHNO and [3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. <i>Nuclear Medicine and Biology</i> , 2008, 35, 11-17.	0.3	47
119	Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. <i>Nuclear Medicine and Biology</i> , 2008, 35, 305-314.	0.3	181
120	Facile Radiosynthesis of Fluorine-18 Labeled Î2-Blockers. Synthesis, Radiolabeling, and ex Vivo Biodistribution of [¹⁸ F]-(2 <i>S</i>) and Tj ETQqO O O rgBT /Overlock 10 Tf 50 302 Td (2 <i>R</i>)-1-(1-Fluoropropan-2-ylamino)ethane. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2008, 51, 5093-5100.	2.9	9
121	Seasonal Variation in Human Brain Serotonin Transporter Binding. <i>Archives of General Psychiatry</i> , 2008, 65, 1072.	13.8	224
122	First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C](+)-PHNO Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2008, 33, 279-289.	2.8	109
123	Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?. <i>Journal of Neuroscience</i> , 2008, 28, 9850-9856.	1.7	86
124	Serotonin2A receptor binding potential in people with aggressive and violent behaviour. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 499-508.	1.4	39
125	Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Response—A Double-Blind PET Study in Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 1209-1215.	2.8	118
126	Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [18F]F-PHNO. <i>Nuclear Medicine and Biology</i> , 2007, 34, 195-203.	0.3	24

#	ARTICLE	IF	CITATIONS
127	Misunderstandings About How to Choose a Reference Region. <i>Biological Psychiatry</i> , 2007, 61, 1314.	0.7	4
128	Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2007, 62, 327-331.	0.7	186
129	Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 857-871.	2.4	88
130	Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. <i>Psychopharmacology</i> , 2007, 193, 539-545.	1.5	61
131	High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO. <i>Biological Psychiatry</i> , 2006, 59, 389-394.	0.7	129
132	In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. <i>Synapse</i> , 2006, 60, 172-183.	0.6	24
133	Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. <i>Synapse</i> , 2006, 60, 314-318.	0.6	11
134	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , 2006, 97, 1089-1103.	2.1	145
135	Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 330-344.	2.4	100
136	Elevated Monoamine Oxidase A Levels in the Brain. <i>Archives of General Psychiatry</i> , 2006, 63, 1209.	13.8	507
137	Elevated Putamen D ₂ Receptor Binding Potential in Major Depression With Motor Retardation: An [¹¹ C]Raclopride Positron Emission Tomography Study. <i>American Journal of Psychiatry</i> , 2006, 163, 1594-1602.	4.0	139
138	Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N ^ε -(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): A radiolabelled glycogen synthase kinase-3 β specific inhibitor for PET studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5270-5273.	1.0	57
139	Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4153-4160.	2.9	218
140	Distinct effects of sleep deprivation on binding to norepinephrine and serotonin transporters in rat brain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 297-303.	2.5	58
141	Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans. <i>Biological Psychiatry</i> , 2005, 58, 825-830.	0.7	92
142	PET imaging of DA neurotransmission using agonist versus antagonist radiotracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S715-S715.	2.4	0
143	The D2-agonist radiotracer [11C]-(+)-PHNO shows a marked increase in sensitivity to amphetamine challenges when compared to [11C]raclopride in the cat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S611-S611.	2.4	0
144	Evaluation of [11C]-(+)-PHNO as an agonist radiotracer for imaging high-affinity dopamine D2 receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S594-S594.	2.4	0

#	ARTICLE	IF	CITATIONS
145	Brain Serotonin Transporter Binding Potential Measured With Carbon-11 Labeled DASB Positron Emission Tomography. Archives of General Psychiatry, 2004, 61, 1271.	13.8	264
146	Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. American Journal of Psychiatry, 2004, 161, 1620-1625.	4.0	146
147	Quantitative validation of an intracerebral α -sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [^{11}C]raclopride in rats. Synapse, 2004, 52, 89-99.	0.6	24
148	A rapid one-step radiosynthesis of the ^{125}I -amyloid imaging radiotracer N-methyl- ^{11}C -2-(4-methylaminophenyl)-6-hydroxybenzothiazole ([^{11}C]-6-OH-BTA-1). Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 679-682.	0.5	88
149	Amphetamine pretreatment induces a change in both D ₂ -Receptor density and apparent affinity: a [^{11}C]raclopride positron emission tomography study in cats. Biological Psychiatry, 2004, 55, 1188-1194.	0.7	40
150	Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: An [^{18}F]MPPF positron emission tomography study. Biological Psychiatry, 2004, 56, 587-591.	0.7	40
151	Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [^{11}C]DASB Positron Emission Tomography Study. American Journal of Psychiatry, 2004, 161, 826-835.	4.0	464
152	[^{11}C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse, 2003, 47, 123-133.	0.6	67
153	Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nuclear Medicine and Biology, 2003, 30, 85-92.	0.3	86
154	Dysfunctional Attitudes and 5-HT ₂ Receptors During Depression and Self-Harm. American Journal of Psychiatry, 2003, 160, 90-99.	4.0	254
155	In vitro and in vivo characterisation of [^{11}C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nuclear Medicine and Biology, 2002, 29, 509-515.	0.3	150
156	Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology, 2002, 163, 102-105.	1.5	134
157	Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [^{11}C]McN 5652, [^{11}C]ADAM, [^{11}C]DASB, [^{11}C]DAPA, and [^{11}C]AFM. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1377-1398.	2.4	111
158	Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [^{11}C]McN 5652, [^{11}C]ADAM, [^{11}C]DASB, [^{11}C]DAPA, and [^{11}C]AFM. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1377-1398.	2.4	60
159	Comparison of (+)- ^{11}C -McN5652 and ^{11}C -DASB as serotonin transporter radioligands under various experimental conditions. Journal of Nuclear Medicine, 2002, 43, 678-92.	2.8	81
160	Carbon-11 labelled cholecystininB antagonists. Life Sciences, 2001, 68, 1223-1230.	2.0	7
161	Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [^{11}C]DASB PET Imaging Study. American Journal of Psychiatry, 2001, 158, 1843-1849.	4.0	335
162	Lower dopamine transporter binding potential in striatum during depression. NeuroReport, 2001, 12, 4121-4125.	0.6	242

#	ARTICLE	IF	CITATIONS
163	Syntheses of the phosphodiesterase-4 inhibitors [¹¹ C]Ro 20-1724, R-, R/S- and S-[¹¹ C]rolipram. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 373-384.	0.5	15
164	Further progress on a remarkably simple captive solvent method for [¹¹ C]methylations. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S999.	0.5	3
165	An admonition when measuring the lipophilicity of radiotracers using counting techniques. Applied Radiation and Isotopes, 2001, 54, 203-208.	0.7	174
166	Positron Emission Tomography Quantification of [¹¹ C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1342-1353.	2.4	262
167	The Effect of Paroxetine on 5-HT _{2A} Receptors in Depression: An [¹⁸ F]Setoperone PET Imaging Study. American Journal of Psychiatry, 2001, 158, 78-85.	4.0	222
168	Synthesis of R-[N-methyl- ¹³ C]SKF 82957 from [¹³ C]methyl iodide and [¹³ C]methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 701-710.	0.5	1
169	Increased dopamine D ₂ receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 2000, 152, 174-180.	1.5	249
170	Radiotracer synthesis from [¹¹ C]-iodomethane: a remarkably simple captive solvent method. Nuclear Medicine and Biology, 2000, 27, 529-532.	0.3	194
171	Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of ¹¹ C-Labeled 2-(Phenylthio)araalkylamines. Journal of Medicinal Chemistry, 2000, 43, 3103-3110.	2.9	242
172	Imaging of cAMP-specific phosphodiesterase-IV: Comparison of [¹¹ C]Rolipram and [¹¹ C]Ro 20-1724 in rats. Synapse, 1999, 31, 41-50.	0.6	28
173	Analogues of WAY 100635 as radiotracers for in vivo imaging of 5-HT _{1A} receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 611-620.	0.5	12
174	Radiosynthesis of carbon-11 labelled N-methyl-2-(arylthio)benzylamines: potential radiotracers for the serotonin reuptake receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1277-1288.	0.5	65
175	Serotonin 5-HT ₂ Receptors in Schizophrenia: A PET Study Using [¹⁸ F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects. American Journal of Psychiatry, 1999, 156, 72-78.	4.0	108
176	Derivatives of way 100635 as potential imaging agents for 5-HT _{1A} receptors: syntheses, radiosyntheses, and in vitro and in vivo evaluation. Nuclear Medicine and Biology, 1998, 25, 769-776.	0.3	39
177	5-HT ₂ and D ₂ Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. American Journal of Psychiatry, 1998, 155, 921-928.	4.0	359
178	In vivo evaluation of [¹¹ C]- and [¹⁸ F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nuclear Medicine and Biology, 1996, 23, 141-146.	0.3	65
179	[¹⁸ F]fluoroalkyl analogues of the potent 5-HT _{1A} antagonist WAY 100635: Radiosyntheses and in vivo evaluation. Nuclear Medicine and Biology, 1996, 23, 487-490.	0.3	30
180	Solid-phase radiosynthesis of [¹¹ C]WAY 100635. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 149-154.	0.5	20

#	ARTICLE	IF	CITATIONS
181	Synthesis of two radiofluorinated cocaine analogues using distilled 2-[18F]fluoroethyl bromide. Applied Radiation and Isotopes, 1995, 46, 765-770.	0.7	45
182	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. Life Sciences, 1995, 57, PL103-PL107.	2.0	204
183	Facile radiolabelling and purification of 2 ¹² -[O-11CH3]-carbomethoxy-3 ¹² -aryltropanes: Radiotracers for the dopamine transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 759-765.	0.5	28
184	Comparison of [11C]diprenorphine and [11C]carfentanil in vivo binding to opiate receptors in man using a dual detector system. European Journal of Pharmacology, 1994, 257, 195-197.	1.7	14
185	Decreased hippocampal muscarinic cholinergic receptor binding measured by 123I-iododexetimide and single-photon emission computed tomography in epilepsy. Annals of Neurology, 1993, 34, 235-238.	2.8	35
186	Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2 ¹² -carbomethoxy-3 ¹² -(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). Journal of Labelled Compounds and Radiopharmaceuticals, 1993, 33, 147-152.	0.5	45
187	Measurement of Benzodiazepine Receptor Number and Affinity in Humans Using Tracer Kinetic Modeling, Positron Emission Tomography, and [¹¹ C]Flumazenil. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 656-667.	2.4	82
188	Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with 11C-N-methylspiperone. Psychiatry Research, 1993, 49, 219-237.	1.7	111
189	Chemistry of Tracers for Positron Emission Tomography. , 1993, , 55-74.		0
190	Synthesis and biodistribution of a new radiotracer for in vivo labeling of serotonin uptake sites by PET, cis-N,N-[11C]dimethyl-3-(2,4-dichlorophenyl)-indanamine (cis-[11C]DDPI). International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1992, 19, 549-553.	0.3	5
191	In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Synapse, 1992, 12, 236-241.	0.6	6
192	Effects of Vasopressin on Blood-Brain Transfer of Methionine in Dogs. Journal of Neurochemistry, 1992, 59, 1421-1429.	2.1	11
193	Imaging Muscarinic Cholinergic Receptors in Human Brain in vivo with SPECT, [123I]4-Iododexetimide, and [123I]4-Iodolevetimide. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 562-570.	2.4	60
194	Synthesis of a Radiotracer for Studying k-Subtype Opiate Receptors: N-[11C-methyl]-N-(trans-2-pyrrolidinyl-cyclohexyl)-3,4-dichlorophenylacetamide ([11C](κ)U-50488H). Journal of Labelled Compounds and Radiopharmaceuticals, 1992, 31, 81-89.	0.5	12
195	In vivo biodistribution of two [18F]-labelled muscarinic cholinergic receptor ligands: 2-[18F]- and 4-[18F]-fluorodexetimide. Life Sciences, 1991, 48, 1385-1394.	2.0	18
196	Radiosynthesis and evaluation of N-(3-[18F]fluoropropyl)paroxetine as a radiotracer for in vivo labeling of serotonin uptake sites by PET. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 791-796.	0.3	14
197	Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [¹¹ C]Diprenorphine and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 204-219.	2.4	94
198	Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Annals of Neurology, 1991, 30, 3-11.	2.8	189

#	ARTICLE	IF	CITATIONS
199	Radiosynthesis of [¹¹ C]-N-methylacyclovir. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1991, 29, 765-768.	0.5	6
200	Effects of atropine treatment on in vitro and in vivo binding of 4-[¹²⁵ I]-dexetimide to central and myocardial muscarinic receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991, 18, 447-452.	2.2	10
201	Special Problems Associated with the Synthesis of High Specific Activity Carbon-11 Labeled Radiotracers. , 1991, , 21-30.		2
202	Comparison of [¹¹ C]Diprenorphine and [¹¹ C]Carfentanil Binding to Opiate Receptors in Humans by Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1990, 10, 484-492.	2.4	82
203	Reductive amination of [¹⁸ F]fluorobenzaldehydes: Radiosyntheses of [2- ¹⁸ F]- and [4- ¹⁸ F]fluorodexetimides. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1990, 28, 1189-1199.	0.5	53
204	Facile synthesis of [¹¹ C]buprenorphine for positron emission tomographic studies of opioid receptors. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1990, 41, 745-752.	0.5	19
205	Synthesis of a selective serotonin uptake inhibitor: [¹¹ C]citalopram. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1990, 41, 541-543.	0.5	28
206	Radiosynthesis of [¹¹ C]nifedipine and [¹¹ C]nicardipine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1989, 27, 589-598.	0.5	11
207	Preparation of [¹¹ C]- and [¹²⁵ I]MB: a dopamine D-2 receptor antagonist. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1989, 40, 369-373.	0.5	5
208	Synthesis and in vivo characterization of d-(+)-(N1-[¹¹ C]methyl)-2-Br-LSD: a radioligand for positron emission tomographic studies of serotonin 5-HT ₂ receptors. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1989, 16, 697-704.	0.3	3
209	Synthesis and biological evaluation of iodine-125- and iodine-123-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1057-1062.	2.9	58
210	Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. <i>Annals of Neurology</i> , 1988, 23, 231-237.	2.8	253
211	Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [¹¹ C]dexetimide and [¹¹ C]levetamide. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1988, 39, 291-295.	0.5	59
212	(N-Methyl-[¹¹ C])pyrilamine, a radiotracer for histamine H-1 receptors: Radiochemical synthesis and biodistribution study in mice. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1988, 15, 605-610.	0.3	7
213	Localization of serotonin 5-HT ₂ receptors in living human brain by positron emission tomography using N1-([¹¹ C]-methyl)-2-BR-LSD. <i>Synapse</i> , 1987, 1, 393-398.	0.6	94
214	Radiosynthesis of a selective dopamine D-1 receptor antagonist: R(+)-7-chloro-8-hydroxy-3-[¹¹ C]methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine ([¹¹ C]SCH 23390). <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1987, 38, 305-306.	0.5	21
215	Synthesis of carbon-11 labeled diprenorphine: A radioligand for positron emission tomographic studies of opiate receptors. <i>Tetrahedron Letters</i> , 1987, 28, 4015-4018.	0.7	38
216	Imaging benzodiazepine receptors in man with [¹¹ C]suriclone by positron emission tomography. <i>European Journal of Pharmacology</i> , 1986, 122, 381-383.	1.7	49

#	ARTICLE	IF	CITATIONS
217	I-125 and I-123 labelled iodobenzyl bromide, a useful alkylating agent for radiolabelling biologically important molecules. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1986, 23, 83-93.	0.5	12
218	An improved synthesis of (3-N-[11C]methyl)piperone. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1986, 37, 433-434.	0.5	63
219	Imaging Opiate Receptors in the Human Brain by Positron Tomography. <i>Journal of Computer Assisted Tomography</i> , 1985, 9, 231-236.	0.5	237
220	Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. <i>The International Journal of Applied Radiation and Isotopes</i> , 1985, 36, 303-306.	0.7	136